Mitotic rate in node-positive stage III melanoma: it might be as important a prognostic factor as node number

被引:4
|
作者
Tas, Faruk [1 ]
Erturk, Kayhan [2 ]
机构
[1] Istanbul Univ, Inst Oncol, TR-34390 Istanbul, Turkey
[2] Koc Univ, Dept Med Oncol, Istanbul, Turkey
关键词
melanoma; stage III; mitotic rate; node-positive; AMERICAN JOINT COMMITTEE;
D O I
10.1093/jjco/hyab031
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Stage III melanoma is a heterogenous disease, and the number of tumor-involved lymph nodes is the most significantly unfavorable prognostic indicator for relapse and outcome. The aim of this study is to investigate the possible effects of the various clinicopathological factors on the course of node-positive stage III disease. Methods: A total of 389 node-positive stage III cutaneous melanomas were included in the study and analyzed retrospectively. All underwent pathological nodal staging by sentinel lymph node biopsy or elective lymph node dissection. Results: The group was male-dominant (59%) and the median age was 50 years. The largest group of patients was N1 (n = 221, 56.8%) followed by N2 (n = 105, 27.0%) and N3 (n = 63, 16.2%). N1 melanomas were less frequently associated with relapses than melanomas with multiple lymph node metastases (P = 0.05). The 5-year relapse-free survival rate was 37.9%. The melanomas with multiple lymph nodes metastases (P = 0.01), higher mitotic rate (P = 0.005) and ulceration (P = 0.02) had worse RFS. In the multivariate analysis only the significances of the N2-N3 stage (P = 0.016) and higher mitosis (P = 0.012) persisted. The severe lymph node metastasis (N2-N3) was associated with a higher mortality rate in comparison with the single nodal involvement (P = 0.05). The 5-year overall survival rate was 52.1%. Presence of relapse (P = 0.0001), higher mitotic rate (P = 0.03) and N2-N3 stage (P = 0.04) were inversely correlated with the overall survival. When relapse was included in the multivariate analysis, it was the only significant prognostic factor on survival (P = 0.0001), whereas mitosis became the only significant factor on survival with the exclusion of relapse from the multivariate analysis (P = 0.031). Conclusion: In node-positive stage III melanoma, tumor mitotic rate might be just as significant a prognostic indicator as the metastatic lymph node number.
引用
收藏
页码:873 / 878
页数:6
相关论文
共 50 条
  • [31] Use of Completion Lymph Node Dissection for Sentinel Lymph Node-Positive Melanoma
    Herb, Joshua N.
    Dunham, Lisette N.
    Ollila, David W.
    Stitzenberg, Karyn B.
    Meyers, Michael O.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2020, 230 (04) : 515 - 524
  • [32] Sentinel Lymph Node Genes to Predict Prognosis in Node-Positive Melanoma Patients
    Hongying Hao
    Deyi Xiao
    Jianmin Pan
    Jifu Qu
    Michael Egger
    Sabine Waigel
    Mary Ann G. Sanders
    Wolfgang Zacharias
    Shesh N. Rai
    Kelly M. McMasters
    Annals of Surgical Oncology, 2017, 24 : 108 - 116
  • [33] Sentinel Lymph Node Genes to Predict Prognosis in Node-Positive Melanoma Patients
    Hao, Hongying
    Xiao, Deyi
    Pan, Jianmin
    Qu, Jifu
    Egger, Michael
    Waigel, Sabine
    Sanders, Mary Ann G.
    Zacharias, Wolfgang
    Rai, Shesh N.
    McMasters, Kelly M.
    ANNALS OF SURGICAL ONCOLOGY, 2017, 24 (01) : 108 - 116
  • [34] Adjuvant radiation therapy in women with stage III node-positive uterine cancer
    Schmid, S.
    Hsu, I.
    Hu, J. M.
    Powell, C. B.
    Chen, L.
    Osann, K.
    Kapp, D. S.
    Chan, J. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [35] Completion Node Dissection in Patients with Sentinel Node-Positive Melanoma of the Head and Neck
    Smith, Valerie A.
    Cunningham, Joan E.
    Lentsch, Eric J.
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2012, 146 (04) : 591 - 599
  • [36] The Role of Completion Lymph Node Dissection for Sentinel Lymph Node-Positive Melanoma
    Hieken, Tina J.
    Kane, John M., III
    Wong, Sandra L.
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (04) : 1028 - 1034
  • [37] Pelvic Lymph Node Dissection Is Beneficial in Subsets of Patients with Node-positive Melanoma
    Brian Badgwell
    Yan Xing
    Jeffrey E. Gershenwald
    Jeffrey E. Lee
    Paul F. Mansfield
    Merrick I. Ross
    Janice N. Cormier
    Annals of Surgical Oncology, 2007, 14 : 2867 - 2875
  • [38] The Role of Completion Lymph Node Dissection for Sentinel Lymph Node-Positive Melanoma
    Tina J. Hieken
    John M. Kane
    Sandra L. Wong
    Annals of Surgical Oncology, 2019, 26 : 1028 - 1034
  • [39] The prognostic significance of sentinel node tumour burden in melanoma patients: An international, multicenter study of 1539 sentinel node-positive melanoma patients
    van der Ploeg, Augustinus P. T.
    van Akkooi, Alexander C. J.
    Haydu, Lauren E.
    Scolyer, Richard A.
    Murali, Rajmohan
    Verhoef, Cornelis
    Thompson, John F.
    Eggermont, Alexander M. M.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (01) : 111 - 120
  • [40] Stratification might be appropriate for patients with node-positive uterine cancer
    Nature Clinical Practice Oncology, 2007, 4 (12): : 679 - 679